The 5 most recent market catalysts affecting $ELDN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 85
Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society
Eledon Pharmaceuticals reported updated long-term Phase 2 data for its drug tegoprubart, demonstrating statistically significant improvements in kidney function and a reduction in …
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 85
Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026
Eledon Pharmaceuticals (ELDN) received FDA Fast Track designation for tegoprubart, a significant regulatory milestone that can expedite the drug's development and review for preven…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 85
Eledon Pharmaceuticals Submits IND To FDA For Registrational Tegoprubart Study In Islet Cell Transplantation For Type 1 Diabetes; Reaffirms Q4 2026 Initiation Of Phase 3 LEGACY Kidney Transplant Trial
This headline is a strong positive catalyst for Eledon Pharmaceuticals (ELDN). The IND submission for tegoprubart in islet cell transplantation opens up a new, potentially lucrativ…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate
Eledon Pharma (ELDN) announced its Q2 earnings, reporting a loss of $(0.27) per share, which was significantly worse than the analyst consensus estimate of $(0.16). This miss of 68…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 65
Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12
Rodman & Renshaw's initiation of coverage on Eledon Pharmaceuticals with a 'Buy' rating and a $12 price target is a positive development for the company. Analyst coverage, especial…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.